These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. Foster RH; Goa KL CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224 [TBL] [Abstract][Full Text] [Related]
5. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Strawn JR; Mills JA; Poweleit EA; Ramsey LB; Croarkin PE Pharmacotherapy; 2023 Jul; 43(7):675-690. PubMed ID: 36651686 [TBL] [Abstract][Full Text] [Related]
6. The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. Vaughn SE; Strawn JR; Poweleit EA; Sarangdhar M; Ramsey LB J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34209709 [TBL] [Abstract][Full Text] [Related]
10. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Jing E; Straw-Wilson K Ment Health Clin; 2016 Jul; 6(4):191-196. PubMed ID: 29955469 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. Lobo ED; Quinlan T; Prakash A Clin Pharmacokinet; 2014 Aug; 53(8):731-40. PubMed ID: 24989060 [TBL] [Abstract][Full Text] [Related]
12. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder. Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343 [TBL] [Abstract][Full Text] [Related]
14. An emerging role for escitalopram in the treatment of obsessive-compulsive disorder. Hedges DW; Woon FL Neuropsychiatr Dis Treat; 2007 Aug; 3(4):455-61. PubMed ID: 19300574 [TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Liu X; Chen Y; Faries DE Clinicoecon Outcomes Res; 2011; 3():63-72. PubMed ID: 21935334 [TBL] [Abstract][Full Text] [Related]
16. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Kirino E Patient Prefer Adherence; 2012; 6():853-61. PubMed ID: 23271894 [TBL] [Abstract][Full Text] [Related]
17. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. Schoretsanitis G; Paulzen M; Unterecker S; Schwarz M; Conca A; Zernig G; Gründer G; Haen E; Baumann P; Bergemann N; Clement HW; Domschke K; Eckermann G; Egberts K; Gerlach M; Greiner C; Havemann-Reinecke U; Hefner G; Helmer R; Janssen G; Jaquenoud-Sirot E; Laux G; Messer T; Mössner R; Müller MJ; Pfuhlmann B; Riederer P; Saria A; Schoppek B; Silva Gracia M; Stegmann B; Steimer W; Stingl JC; Uhr M; Ulrich S; Waschgler R; Zurek G; Hiemke C World J Biol Psychiatry; 2018 Apr; 19(3):162-174. PubMed ID: 29493375 [TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder in children and adolescents. Williams JS; Moore T; Collins CL; Thomas KA J Pediatr Pharmacol Ther; 2003 Jul; 8(3):177-86. PubMed ID: 23118677 [TBL] [Abstract][Full Text] [Related]
19. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048 [TBL] [Abstract][Full Text] [Related]
20. Vortioxetine for depression in adults. Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]